Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 216

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

Wilcox, M. H., Corey, G. R., Talbot, G. H., Thye, D., Friedland, D., Baculik, T., on behalf of the CANVAS 2 investigators, Manos, P., Lee, P., Bush, L., DeSanto, J., Jauregui-Peredo, L., Sheftel, T., Pullman, J., Schrock, C., Standiford, H., Mason, R., Guetzkow, J., Lucasti, C., Surber, J., Lee, S., Samonte, V., Rodriguez, C. G., Altclas, J. D., Bergallo, C. E., Mastruzzo, M. A., Morera, G. I., Prieto, S. E., Remolif, C. G., Timmerman, A., Freire, A., Calvo, M., Chain, C., Llancaqueo, A., Amaya, G., Rodriguez, E., Osipov, I. S., Konychev, A. V., Shlyapnikov, S. A., Shulutko, A. M., Zuckerman, J., Bachter, D., Kohl, P., Schilling, M., Kulig, J., Hartwich, A., Szyber, P., Rudzki, S., Kolomecki, K., Drazkiewicz, M., Gutowska-Jablonska, M., Majewski, W., Trautinger, F., Schandalik, R., Pavars, A., Lovcinoskis, V., Gardovskis, J., Hartmane, I., Zarembo, E., Bezrodny, B. G., Datsenko, O. B., Stasyshyn, O. V., Ganzhyi, V. V.·2010·Journal of Antimicrobial Chemotherapy

Abstract

OBJECTIVES: New therapies for complicated skin and skin structure infections (cSSSIs) are needed because of significant morbidity and increasing antimicrobial resistance. Methicillin-resistant Staphylococcus aureus (MRSA) is a common cause of cSSSIs. Ceftaroline fosamil, a novel parenteral cephalosporin with excellent in vitro activity against Gram-positive pathogens, including MRSA, and many Gram-negative pathogens, was evaluated as therapy for cSSSIs in a multinational Phase III study. The primary study objective was to determine non-inferiority [lower limit of 95% confidence interval (CI), -10%] in the clinical cure rate of ceftaroline fosamil monotherapy to that achieved with vancomycin plus aztreonam combination therapy in the clinically evaluable (CE) and modified intent-to-treat (MITT) analysis populations. METHODS: Adult patients with cSSSIs requiring intravenous therapy received 600 mg of ceftaroline fosamil every 12 h or 1 g of vancomycin plus 1 g of aztreonam every 12 h for 5-14 days (randomized 1 : 1). Clinical and microbiological response, adverse events (AEs) and laboratory tests were assessed. Registration number NCT00423657 (http://clinicaltrials.gov/ct2/show/NCT00423657). RESULTS: The study enrolled 694 patients, 348 of whom received ceftaroline fosamil and 346 of whom received vancomycin plus aztreonam. The treatment groups had comparable baseline characteristics. Clinical cure rates for the ceftaroline fosamil and vancomycin plus aztreonam groups were similar in the CE (92.2%, 271/294 versus 92.1%, 269/292; 95% CI, -4.4, 4.5) and MITT (85.1%, 291/342 versus 85.5%, 289/338; 95% CI, -5.8, 5.0) populations, respectively. MRSA cSSSIs were cured in 91.4% (64/70) of patients in the ceftaroline fosamil group and 93.3% (56/60) of patients in the vancomycin plus aztreonam group. The microbiological success rate in the microbiologically evaluable population was 92.9% and 95.0% for ceftaroline fosamil and vancomycin plus aztreonam, respectively. Ceftaroline fosamil and vancomycin plus aztreonam had similar rates of AEs, serious AEs and discontinuations because of an AE. The most common AEs for ceftaroline fosamil and vancomycin plus aztreonam included diarrhoea (6.5% versus 4.4%), nausea (6.2% versus 5.6%), headache (5.3% versus 5.3%) and pruritus (3.8% versus 8.3%), respectively. CONCLUSIONS: Ceftaroline fosamil demonstrated high clinical cure and microbiological success rates, was efficacious against cSSSIs caused by MRSA and other common cSSSI pathogens and was generally well tolerated. Monotherapy with ceftaroline fosamil has the potential to provide an alternative treatment for cSSSIs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jac/dkq255

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 216

Metadata

Authors
Wilcox, M. H., Corey, G. R., Talbot, G. H., Thye, D., Friedland, D., Baculik, T., on behalf of the CANVAS 2 investigators, Manos, P., Lee, P., Bush, L., DeSanto, J., Jauregui-Peredo, L., Sheftel, T., Pullman, J., Schrock, C., Standiford, H., Mason, R., Guetzkow, J., Lucasti, C., Surber, J., Lee, S., Samonte, V., Rodriguez, C. G., Altclas, J. D., Bergallo, C. E., Mastruzzo, M. A., Morera, G. I., Prieto, S. E., Remolif, C. G., Timmerman, A., Freire, A., Calvo, M., Chain, C., Llancaqueo, A., Amaya, G., Rodriguez, E., Osipov, I. S., Konychev, A. V., Shlyapnikov, S. A., Shulutko, A. M., Zuckerman, J., Bachter, D., Kohl, P., Schilling, M., Kulig, J., Hartwich, A., Szyber, P., Rudzki, S., Kolomecki, K., Drazkiewicz, M., Gutowska-Jablonska, M., Majewski, W., Trautinger, F., Schandalik, R., Pavars, A., Lovcinoskis, V., Gardovskis, J., Hartmane, I., Zarembo, E., Bezrodny, B. G., Datsenko, O. B., Stasyshyn, O. V., & Ganzhyi, V. V.
Venue
Journal of Antimicrobial Chemotherapy
Published
2010-11-01
Volume
65
Issue
Supplement 4
Pages
iv53-iv65
ISSN
  • 0305-7453 (ISSN-L)
  • 1460-2091
OpenAlex
W2015652530
Cited by
216
References
3
FWCI
14.41
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. https://app.cochat.ai/papers/10.1093/jac/dkq255
The paper
Wilcox, M. H., Corey, G. R., Talbot, G. H., Thye, D., Friedland, D., Baculik, T., on behalf of the CANVAS 2 investigators, Manos, P., Lee, P., Bush, L., DeSanto, J., Jauregui-Peredo, L., Sheftel, T., Pullman, J., Schrock, C., Standiford, H., Mason, R., Guetzkow, J., Lucasti, C., . . . Ganzhyi, V. V. (2010). CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkq255

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.